Subacute Cutaneous Lupus Erythematosus (SCLE) Medication
- Author: Jeffrey P Callen, MD; Chief Editor: William D James, MD more...
Medication Summary
The basic therapy of skin disease uses sun-protection methods, such as sunscreens, sun-protective clothing, and alteration of exposure by decreasing activities during times of high intensity UV light. Topical corticosteroids are used and selected by the appropriate strength for the area of the body. Intralesional injection of triamcinolone acetonide is useful for individual recalcitrant lesions. Antimalarials are the mainstay of systemic therapy and are associated with lower rates of disease progression and lower risk of thrombovascular disease.[21, 22]
Anecdotal reports or small, open-label trials, as reported by Callen, suggest that the following agents may be of use in some patients[23, 24, 25, 26, 27, 28, 29, 30] :
- Dapsone
- Quinacrine combined with either hydroxychloroquine or chloroquine
- Auranofin
- Thalidomide
- Isotretinoin
- Acitretin
- Azathioprine
- Methotrexate
- Mycophenolate mofetil
- Phenytoin
Antimalarials
Class Summary
Antimalarials have immunomodulatory effects that may improve symptoms of the disease. Hydroxychloroquine is the drug of choice for systemic therapy of subacute cutaneous lupus erythematosus (SCLE). Chloroquine is second line. The lowest possible dose needed to control the patient’s disease should be used.
Hydroxychloroquine (Plaquenil)
Hydroxychloroquine inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions. Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.
Chloroquine (Aralen)
Chloroquine inhibits the effects of immune cells, impairing complement-dependent antigen-antibody reactions.
Leprostatic agents
Class Summary
Leprostatic agents may have immunomodulatory effects.
Dapsone
Dapsone's mechanism of action is similar to that of sulfonamides, with competitive antagonists of para-aminobenzoic acid (PABA) preventing the formation of folic acid, inhibiting bacterial growth.
Immunomodulators
Class Summary
Immunomodulators are effective in the treatment of diseases with autoimmune etiology.
Azathioprine (Azasan, Imuran)
Azathioprine antagonizes purine metabolism and inhibits the synthesis of DNA, RNA, and proteins. It may decrease the proliferation of immune cells, which results in lower autoimmune activity.
Thalidomide (Thalomid)
Thalidomide may suppress the excessive production of tumor necrosis factor alpha (TNF-alpha), and it may down-regulate selected cell-surface adhesion molecules involved in leukocyte migration.
If the patient weighs less than 50 kg (110 lb), start at the low end of the dose regimen. Thalidomide can cause severe, life-threatening birth defects and is contraindicated in pregnant women. It is also contraindicated in women of childbearing potential unless they are using 2 forms of reliable contraception and are complying with serial pregnancy testing while on therapy. In addition, thalidomide is contraindicated in sexually active men who are not using latex condoms as barrier contraception.
The drug is available only under a special, restricted distribution program called the STEPS (System for Thalidomide Education and Prescribing Safety) Program. Only prescribers and pharmacists registered with this program may prescribe and dispense thalidomide. For more information, contact the Celgene Corporation at 1-888-423-5436.
Mycophenolate (CellCept, Myfortic)
Mycophenolate inhibits inosine monophosphate dehydrogenase (IMPDH) and suppresses de novo purine synthesis by lymphocytes, thereby inhibiting their proliferation. The drug inhibits antibody production.
Methotrexate (Rheumatrex, Trexall)
Methotrexate reversibly inhibits dihydrofolate reductase; it limits the availability of 1-carbon fragments necessary for the synthesis of purines and the conversion of deoxyuridylate to thymidylate in the synthesis of DNA and cell reproduction. The drug is extensively used for cancer treatment, rheumatoid arthritis, and psoriasis and as a steroid-sparing agent in various autoimmune conditions.
Gold compounds
Class Summary
Gold compounds may regulate immune cell function.
Auranofin (Ridaura)
Gold is taken up by macrophages, which in turn inhibit phagocytosis and lysosomal membrane stabilization. It alters immunoglobulins, decreasing prostaglandin synthesis and lysosomal enzyme activity.
Retinoids
Class Summary
Retinoids play a role in cell growth and differentiation.
Acitretin (Soriatane)
Acitretin is a retinoic acid analogue similar to etretinate and isotretinoin. Etretinate is the main metabolite, and acitretin has demonstrated clinical effects close to those seen with etretinate. The mechanism of action is unknown.
Isotretinoin (Claravis, Amnesteem, Sotret)
Isotretinoin decreases sebaceous gland size and sebum production. It may inhibit sebaceous gland differentiation and abnormal keratinization.
A US Food and Drug Administration (FDA)–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to decrease the risk of pregnancy and unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.
Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. May 2012;166(5):971-5. [Medline]. [Full Text].
Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum. Aug 1995;38(8):1152-6. [Medline].
Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. Jul 1985;103(1):49-51. [Medline].
Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. May 2006;54(5 Suppl):S242-3. [Medline].
Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. Oct 2005;52(10):3073-8. [Medline].
Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. Nov 2005;46(4):266-9. [Medline].
Farhi D, Viguier M, Cosnes A, Reygagne P, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212(1):59-65. [Medline].
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. Mar 2011;164(3):465-72. [Medline].
Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. Mar 2009;145(3):249-53. [Medline].
Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. Jul 7 2009;[Medline].
Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. Sep 1994;21(9):1665-9. [Medline].
Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. Sep 2002;138(9):1175-8. [Medline].
Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum. Sep 2004;50(9):3045-6. [Medline].
Stege H, Budde MA, Grether-Beck S, Richard A, Rougier A, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Eur J Dermatol. Jul-Aug 2002;12(4):VII-IX. [Medline].
Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. Jan 2011;64(1):37-48. [Medline].
Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. Apr 2012;148(4):479-84. [Medline].
Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. Jan 2003;139(1):50-4. [Medline].
Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. Jan 2008;6(1):48-59. [Medline].
Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. Jul 2007;143(7):873-7. [Medline].
Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. Oct 2008;24(5):260-7. [Medline].
James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401-9. [Medline].
Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. Mar 2010;62(3):863-8. [Medline].
Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum. Aug 1988;31(8):1007-13. [Medline].
Callen JP. Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. Oct 2005;19(5):767-84. [Medline].
Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. Feb 2006;47(1):13-27. [Medline].
Huber A, Tuting T, Bauer R, Bieber T, Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol. Oct 2006;155(4):861-2. [Medline].
Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85(6):545-7. [Medline].
Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. Jul 2005;153(1):157-62. [Medline].
Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. Jun 2007;156(6):1321-7. [Medline].
Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to Antimalarial Agents in Cutaneous Lupus Erythematosus: A Prospective Analysis. Arch Dermatol. Jul 18 2011;[Medline].
Print
